Details of the Drug

General Information of Drug (ID: DM5E73H)

Drug Name
Revusiran
Indication
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Phase 3 [1]
Drug Type
siRNA drug
Sequence
>Subunit 1
UGGGAUUUCAUGUAACCAAGAX
>Subunit 2
UCUUGGUUACAUGAAAUCCCAUC
Cross-matching ID
UNII
ZE6EHM8Z3A
DrugBank ID
DB16309
TTD ID
D01ZHB

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transthyretin messenger RNA (TTR mRNA) TTPOYU7 TTHY_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02319005) ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.